Depo-moderin 5ml injectable | allergic reactions, arthritis, osteoarthritis and polyarthritis

Depo-Moderin

40 mg/ml suspension for injection

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
Active substance:

Excipients:

For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
suspension for injection
4. CLINICAL DATA
4.1 Target species
Horses not intended for human consumption, dogs and cats.
4.2 Indications for use, specifying the target species
Dogs: symptomatic treatment of allergic reactions, arthritis, osteoarthritis and polyarthritis.
Cats: symptomatic treatment of allergic reactions
Horses: symptomatic treatment of allergic reactions, arthritis, osteoarthritis, bursitis and tendinitis.

4.4 Special warnings for each target species
Do not administer to equines whose meat or milk is intended for human consumption.
The veterinarian must evaluate each case individually and determine the treatment program
appropriate. When treatment must be withdrawn after prolonged and intensive therapy, the
dose will be gradually reduced.

4.7 Use during pregnancy, lactation or lay
Do not administer the drug during pregnancy. Fetal malformations have been observed
in laboratory animals due to drug administration at the beginning of pregnancy.
Administration in the last third of pregnancy may cause premature or
abortions.

4.9 Amounts to be administered and administration route
Cats:
Intramuscular route: 1-2 mg of methylprednisolone acetate/kg of weight

Dogs:
Intramuscular injection: 1-2 mg methylprednisolone acetate/kg body weight

Intrasynovial route: The average starting dose for a large synovial space is 20 mg.
(equivalent to 0,5 ml). Smaller spaces will require a corresponding dose
minor. If there is excess synovial fluid and more than 1 ml of the product is to be injected, it is
It is advisable to aspirate a volume of fluid comparable to that to be injected.

4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
In case of overdose, symptoms of hypokalaemia may appear, in which case
corticosteroid therapy should be discontinued and the animal administered a solution of
5% potassium chloride by slow intravenous route.
4.11 Timeout
Not applicable.
Do not use in equines whose meat or milk is intended for human consumption.

6.4. Special storage precautions
Protect from light.
Store at a temperature below 25ºC.
6.5 Nature and composition of immediate packaging
Class I hydrolytic glass vial, closed with a chlorobutyl rubber stopper.
Formats:
Box with 1 vial of 1 ml
Box with 4 vials of 1 ml
Box with 1 vial of 5 ml
Box with 5 vials of 5 ml
Not all formats may be marketed.
6.6 Special precautions for disposal of the veterinary medicinal product not
used or, where appropriate, the residues derived from its use
Any unused veterinary medicinal product or residues derived from it must be
disposed of in accordance with local regulations.

8. MARKETING AUTHORIZATION NUMBER
715 ESP
9. DATE OF THE FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION
Date of first authorization: May 12, 1993
Last renewal date: January 13, 2017
10. DATE OF REVISION OF THE TEXT
January 13, 2017
PROHIBITION OF SALE, DISPENSATION AND/OR USE
Dispensing conditions: Medicine subject to a veterinary prescription.
Administration conditions: Exclusive administration by the veterinarian.

DATA SHEET 

VETLOOM